Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683878 · ClinicalTrials.gov registry record · Phase 3
Add-on to Thiazolidinedione (TZD) Failures
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 972
- Enrollment target
NCT00683878 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 972 participants.
The verdict
NCT00683878, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 972 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone. The safety of this treatment will also be studied
Interventions
- DRUG Dapagliflozin
- DRUG Placebo matching Dapagliflozin
- DRUG Thiazolidinedione (Pioglitazone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 972 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00683878
The ClinicalTrials.gov registry entry for NCT00683878 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 972 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dapagliflozin is the first listed.
NCT00683878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00683878 about?
NCT00683878 is a clinical study titled "Add-on to Thiazolidinedione (TZD) Failures". The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone. The safety of this treatment will also be studied
What is the current status of trial NCT00683878?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 972 participants. The study started on 2008-07. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00683878?
The interventions under investigation include: Dapagliflozin (DRUG), Placebo matching Dapagliflozin (DRUG), Thiazolidinedione (Pioglitazone) (DRUG).
Who is sponsoring clinical trial NCT00683878?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.